Home › Funds › BAKER BROS. ADVISORS LP › DSGN

BAKER BROS. ADVISORS LP position in DSGN

DESIGN THERAPEUTICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 2,678,430 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$38.8M, representing 0.20% of its reported portfolio and ranking #41 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.68M sh
Reported value held$38.76M
Portfolio Weight0.20%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's DSGN position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in DSGN in Q3 2023 at 1,500,000 shares (US$3.5M). The position peaked in Q2 2026 at 2,678,430 shares, worth US$38.8M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,678,430 shares valued at US$38.8M — an increase of 92,452 shares quarter over quarter.. Notable position changes include a 30% increase in Q4 2025 (shares rose 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.50M $3.54M New
Q4 2023 1.50M $3.98M Hold
Q1 2024 1.66M $6.70M Add
Q2 2024 1.70M $5.68M Add
Q3 2024 1.74M $9.38M Add
Q4 2024 1.74M $10.76M Hold
Q1 2025 1.74M $6.73M Hold
Q2 2025 1.71M $5.77M Reduce
Q3 2025 1.71M $12.90M Hold
Q4 2025 2.23M $20.95M Add
Q1 2026 2.59M $27.51M Add
Q2 2026 2.68M $38.76M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DSGN and 13F data

DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), Trails Edge Capital Partners, LP (US$29.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DSGN

All DSGN fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held DSGN?

BAKER BROS. ADVISORS LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in DSGN?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.68M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $38.76M, representing 0.20% of its reported portfolio and ranking #41.

Has BAKER BROS. ADVISORS LP been buying or selling DSGN?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in DSGN. The position peaked in Q2 2026 at 2.68M shares.

Which other funds hold DSGN?

Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, Trails Edge Capital Partners, LP, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.